Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
United Laboratories, Tartu University Hospital, Tartu, Estonia.
Eur J Immunol. 2020 Aug;50(8):1234-1236. doi: 10.1002/eji.202048715. Epub 2020 Jul 6.
Profiling antibodies to SARS-CoV-2 can help to assess potential immune response after COVID-19 disease. Luciferase IP system (LIPS) assay is a sensitive method for quantitative detection of antibodies to antigens in their native conformation. We here describe LIPS to detect antibody responses to SARS-CoV-2 spike (S) and nucleocapsid (N) proteins in COVID-19 patients. The antibodies targeted both S and N fragments and gave a high assay sensitivity by identifying 26 out of 26 COVID-19 patients with N antigen or with three protein fragments when combined into a single reaction. The assay correlated well with ELISA method and was specific to COVID-19 as we saw no reactivity among uninfected healthy controls. Our results show that LIPS is a rapid and measurable method to screen antibody responses against SARS-CoV-2 antigens.
对 SARS-CoV-2 抗体进行分析可以帮助评估 COVID-19 疾病后的潜在免疫反应。荧光素酶免疫沉淀系统（LIPS）检测法是一种用于定量检测抗原在其天然构象中抗体的敏感方法。我们在此描述了 LIPS 检测法，用于检测 COVID-19 患者中针对 SARS-CoV-2 刺突（S）和核衣壳（N）蛋白的抗体反应。这些抗体针对 S 和 N 片段，并通过在单个反应中结合三种蛋白片段或 N 抗原来识别 26 名 COVID-19 患者中的 26 名，从而具有很高的检测灵敏度。该检测法与 ELISA 方法相关性良好，并且对 COVID-19 具有特异性，因为我们在未感染的健康对照者中未观察到任何反应性。我们的结果表明，LIPS 是一种快速且可测量的方法，用于筛查针对 SARS-CoV-2 抗原的抗体反应。
